A Randomized Phase II Trial of Short-Course Androgen Deprivation Therapy With or Without Bevacizumab for Patients With Recurrent Prostate Cancer After Definitive Local Therapy.

@article{McKay2016ARP,
  title={A Randomized Phase II Trial of Short-Course Androgen Deprivation Therapy With or Without Bevacizumab for Patients With Recurrent Prostate Cancer After Definitive Local Therapy.},
  author={Rana R. McKay and Amado J. Zurita and Lillian L Werner and Justine Yang Bruce and Michael Anthony Carducci and Mark N. Stein and Elisabeth Heath and Arif Hussain and Hai T. Tran and Christopher J. Sweeney and Robert W. Ross and Philip W. Kantoff and Susan F. Slovin and M Taplin},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2016},
  volume={34 16},
  pages={
          1913-20
        }
}
PURPOSE Patients with recurrent prostate cancer after local treatment make up a heterogeneous population for whom androgen deprivation therapy (ADT) is the usual treatment. The purpose of this randomized phase II trial was to investigate the efficacy and toxicity of short-course ADT with or without bevacizumab in men with hormone-sensitive prostate cancer. PATIENTS AND METHODS Eligible patients had an increasing prostate-specific antigen (PSA) of ≤ 50 ng/mL and PSA doubling time of less than… CONTINUE READING